Abstract
In the last few years a new approach for targeted therapy of human diseases was developed using cytotoxic molecules that were produced by gene fusion techniques. This class of molecules termed chimeric proteins comprises both the cell targeting and the cell killing moieties. As killing moieties, portions of toxins such as pseudomonas exotoxin (PE) or diphtheria toxin (DT) are used. Through ADP-ribosylation, PE and DT act by inactivating elongation factor 2. This causes the irreversible arrest of protein synthesis in eukaryotic cells leading to cell death (Middlebrook and Dorland, 1984). Specificity is then added to the truncated or modified toxins by fusing them with recognition elements that direct the chimeric protein to selected target cells overexpressing a specific receptor/surface marker. Effective chimeric proteins have been constructed by fusing cDNA’s encoding a variety of cytokines, growth factors, single chain antibodies and many other ligands with PE, DT and additional bacterial/plant toxins (Frankel et al., 2000). The specific binding of the targeting moiety of the chimeric protein to a surface receptor/marker expressed by the targeted cells enables the elimination of the particular cell population, sparing other cell types
Original language | American English |
---|---|
Title of host publication | Chimeric Toxins |
Subtitle of host publication | Mechanisms of Action and Therapeutic Applications |
Editors | Haya Lorberboum-Galski, Philip Lazarovici |
Place of Publication | New-York |
Publisher | Taylor & Francis |
Chapter | 6 |
Pages | 135-147 |
Edition | 1st |
ISBN (Electronic) | 9780429218552 |
State | Published - 2002 |